State Key Laboratory of Oncology in South China, Sun Yat-Sen University Cancer Center, Guangzhou, People's Republic of China.
J Surg Oncol. 2011 Sep 1;104(3):236-43. doi: 10.1002/jso.21921. Epub 2011 Apr 7.
The correlation of biomarker expression between primary tumors and corresponding metastases has not yet been well reported in esophageal squamous cell carcinoma (ESCC). This study was to confirm whether primary ESCC tumors differ from their regional metastatic lymph nodes (RMLN) in CyclinD1, p53, E-cadherin, and vascular endothelial growth factor (VEGF) expression and determine prognostic value of their alteration.
There were 134 patients with stage T3N1-3M0 ESCC recruited for the research. Expression of CyclinD1, p53, E-cadherin, and VEGF was evaluated in primary ESCC tumors and their paired RMLN assembled on tissue microarrays by immunohistochemistry (IHC). The comparison of expression in different lesion and their correlation with prognosis was analyzed.
E-cadherin was discordant expression in 55.2% cases and appeared to be more frequently positive in metastatic lymph nodes (P < 0.001). The VEGF expression level was significantly higher in primary tumors (P < 0.001). Combined analysis of VEGF expressions in paired lesions (P = 0.003) and its decreased expression (P = 0.006) were both predictive.
Biomarker expression was discordant between the primary tumor and its paired lymphatic metastasis in over 25% of patient with ESCC. VEGF discordant expression was a new prognostic factor and combined analysis of expression in paired lesions was useful to predict. Analysis of protein expression only in primary tumors would be inadequate to judge prognosis.
在食管鳞状细胞癌(ESCC)中,原发肿瘤与相应转移灶之间的生物标志物表达相关性尚未得到很好的报道。本研究旨在确认原发性 ESCC 肿瘤与局部转移淋巴结(RMLN)在 CyclinD1、p53、E-cadherin 和血管内皮生长因子(VEGF)表达上是否存在差异,并确定其改变的预后价值。
共纳入 134 例 T3N1-3M0 期 ESCC 患者作为研究对象。采用免疫组织化学(IHC)方法在组织微阵列上评估原发性 ESCC 肿瘤及其配对的 RMLN 中 CyclinD1、p53、E-cadherin 和 VEGF 的表达情况。分析不同病变部位表达的差异及其与预后的相关性。
E-cadherin 在 55.2%的病例中表达不一致,且在转移性淋巴结中更常呈阳性(P < 0.001)。原发性肿瘤中 VEGF 的表达水平显著升高(P < 0.001)。配对病变中 VEGF 表达的综合分析(P = 0.003)及其表达降低(P = 0.006)均具有预测价值。
超过 25%的 ESCC 患者的原发性肿瘤与其配对的淋巴结转移之间存在生物标志物表达不一致。VEGF 表达不一致是一个新的预后因素,对其进行综合分析有助于预测。仅对原发性肿瘤进行蛋白表达分析不足以判断预后。